Analystreport

Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) was downgraded by analysts at Kempen & Co from a "buy" rating to a "neutral" rating.

Y-mAbs Therapeutics, Inc.  (YMAB) 
Last y-mabs therapeutics, inc. earnings: 11/13 04:01 pm Check Earnings Report